Warning: Constant WP_TEMP_DIR already defined in /home/fredeln118/domains/vital-imi.eu/public_html/wp-config.php on line 74 VITAL Holds Webinar on ‘Ageing and the germinal centre response to vaccination’ – Vital-Imi
On May 11th VITAL held a webinar where Michelle Linterman, Group Leader at the Babraham Institute and a Fellow of Churchill College, Cambridge, presented “Ageing and the germinal centre response to vaccination”
Michelle Linterman is Group Leader at the Babraham Institute and a Fellow of Churchill College, Cambridge. She is a Lister Institute Prize Fellow and an EMBO Young Investigator.
Her laboratory’s principal research focus is on how different cell types collaborate in the germinal centre to generate a robust antibody response following vaccination.
“Our work combines research in mice, with human vaccination studies to enable us to deliver mechanistic insight into the germinal centre response that is of direct relevance to human health”.
The work of the laboratory is supported by the Biotechnology and Biological Sciences Research Council (UK), The European Research Council (EU), the Dunhill Medical Trust (UK) and UK Research and Innovation (UK).
“As a PhD student, with Prof Carola Vinuesa at the Australian National University, I described the role for follicular helper T cells in autoimmune disease (Linterman et al., J Exp Med, 2009), and characterised key cytokine and costimulatory requirements for this important germinal centre.
During my post-doc with Prof Ken Smith at the University of Camrbridge, I continued to dissect the cellular and molecular mechanisms important for follicular helper T cell biology in both mice, as a first author (Linterman et al., eLife, 2014), and, in humans, as a senior author (Wallin et al., Blood, 2014).
It was during my post-doc that I that suppressive follicular regulatory T cells act within the germinal centre (Linterman et al., Nature Medicine, 2011)”.
You can contact us by using the contact form here.
The VITAL project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806776. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.